Patent Application
20230393164
In the early days of the COVID-19 pandemic, it appeared that children were spared from the disease. However, an increasing number of children worldwide have been reported to develop a rare but severe complication of SARS-CoV-2 exposure called Multisystem Inflammatory Syndrome in Children (MIS-C). Most of the MIS-C cases are reported in geographical areas of high COVID-19 incidence, and most cases occur approximately 3-4 weeks after the local peak of the pandemic. Initially reported as hyperinflammatory shock and “Kawasaki-like” illness, MIS-C has been observed to have overlapping features with toxic shock syndrome, atypical Kawasaki disease, macrophage activation syndrome, and cardiogenic and septic shock. Dilated coronary arteries have been reported in 17-25% of the patients with rare development of coronary artery aneurysms and cardiac collapse. Although most MIS-C patients survive with adequate intensive care, deaths have been reported. The long-term consequences of MIS-C are currently unknown.
Identifying MIS-C is challenging. The primary symptom of MIS-C is fever. However, fever is also one of the most common symptoms prompting evaluation by a pediatrician. By the current CDC guidelines, fever in the setting of any SARS-CoV-2 exposures within the past 4 weeks should prompt suspicion for MIS-C. However, potential SARS-CoV-2 exposure is near-universal, given its community spread. To assess for MIS-C, laboratory evaluation is recommended, including complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), interleukin 6 (IL-6), and albumin. However, many of these labs are non-specific, e.g., elevated neutrophil count on CBC, or elevated CRP. Other laboratory tests take time to be completed, including IL-6, and therefore are less informative at the time of critical clinical decision making. Overall, the assessment of MIS-C could take up to 24 hours and require intensive use of laboratory resources. Accordingly, a rapid, informative detection technology is needed.
In some aspects, this disclosure relates to a system for evaluating MIS-C associated with COVID-19 in pediatric patients. The system may comprise a flowcell with a flow of a liquid containing a plurality of cells through the flowcell. The system may comprise one or more sensors for detecting light scatter, light transmission, electrical impedance, RF conductivity, or combinations thereof as cells pass through the flowcell. The system may comprise a processor for calculating cell population parameters based on a plurality of measurements of individual cells of the same or related types. The processor may evaluate MIS-C based at least in part on one or more of the cell population parameters.
In some aspects, a method may be provided comprising flowing a body fluid sample through a flowcell, irradiating a plurality of cells in the body fluid sample in the flowcell, measuring light scatter and direct current impedance from individual cells of the plurality of cells, analyzing one or more cell population parameters, and evaluating MIS-C associated with SARS-CoV-2 based at least in part on the one or more cell population parameters.
One or more cell population parameters can relate to a cell population selected from the group consisting of red blood cells (RBC), white blood cells (WBC), including neutrophils (Ne), early granulocytes (EGC), monocytes, eosinophils (Eo), basophils, and lymphocytes (Ly).
Depending on the technology used, the parameters will vary. In Beckman Coulter's DxH hematology analyzers (including but not limited to the DxH 800 and DxH 900), the WBC differential sample is directed through the flow cell and analyzed with a multi-transducer module composed of a diode laser module, flow cell and two optical sensor assemblies. At least seven parameter measurements are performed that characterize cellular size, shape and morphology. The seven parameters—impedance, radio frequency, and five laser light scatter measurements—are captured simultaneously for each cell passing through the flow cell. These parameters generally measure volume, conductivity, and scatter (VCS).
In addition, each parameter measurement includes four pulse shape attributes. These measurements plus time provide a total of 29 distinct measurements per cellular event. The impedance measurement (volume) is an indicator of three-dimensional cell size. The radio frequency measurement (conductivity) provides information regarding the internal structure of the cell, such as cellular density. In addition to the volume and conductivity measurements, five light scatter measurements—axial light loss (ALL or a derivative thereof, e.g., AL2), low angle light scatter (LALS), lower median angle light scatter (LMALS), upper median angle light scatter (UMALS), and median angle light scatter (MALS) —define the granularity and lobularity characteristics of each cellular event.
The DxH systems use high-speed, high-resolution analog-to-digital conversion with Digital Signal Processing (DSP) circuitry to measure multiple parameters for each cellular event. DSP algorithms analyze the cellular data digitally, providing cellular definition and resolution. Differential accuracy and flagging technology are obtained by combining the additional light scatter measurements with data analysis techniques to further define and separate cell populations. For example, in some cases, MALS may be transformed to a modified rotated MALS (RMALS) parameter through a mathematical transformation to eliminate overlap and create distinct neutrophil, lymphocyte, monocyte and eosinophil populations, enabling optimal analysis and visual confidence in the results. Current internal and visual differential data transformations include: RMALS (rotated MALS), opacity (conductivity minus the size aspect), SOP (stretched opacity), and non-linear AL2 transformations. The DxH systems report “VCS parameters”.
Other hematology analyzers, such as those manufactured by Abbott, Sysmex, and Mindray, use the cluster of differentiation (CD) system to differentiate white blood cell populations. CD molecules can act in numerous ways, often acting as receptors or ligands; by which a signal cascade is initiated, altering the behavior of the cell. Some CD proteins do not play a role in cell signaling, but have other functions, such as cell adhesion. The CD system nomenclature commonly used to identify cell markers thus allows cells to be defined based on what molecules are present on their surface. There are more than 350 CD molecules identified for humans. For example, monocytes can be identified with CD45+ and CD14+. Using fluorescently labeled antibodies, these cell markers can used to sort cells. Fluorescence activated cell sorting (FACS) provides a method of sorting a heterogeneous mixture of cells into two or more containers, a single cell at a time, based upon the specific light scattering and fluorescent characteristics of each cell. Fluorescence flow cytometry or FACS may also provide information about cell composition of a labeled cell. For example, information about cell density or complexity may be obtained by measuring light scattered by the cell and information about cell size and internal structure may be obtained by measuring the fluorescence signal intensity of the cell. Systems based on fluorescence flow cytometry or FACS report “FACS parameters.”
VCS parameters and FACS parameters are both described in the art.
In some methods described herein, the one or more cell population parameters may be VCS parameters or FACS parameters. In some methods, the cell population parameters may preferably be VCS parameters. In some methods, the cell population parameters may be VCS parameters selected from the group consisting of Ne_DC_Mean, Egc_Lmals_Mean, Egc_Mals_Mean (EGC), Ne_Lmals_Mean, Diff_LDW_Value, Ly_DC_SD, Ne_Mals_Mean, Rbc, Mo_DC_SD, MDW, Mo_DC_Mean, Ne_All_SD, Hct, Ne_DC_SD, Hgb, Ne_All_Mean, Ly_All_SD, NNrbc_Op_SD, Eo_All_Mean, Ly_Lmals_SD, Ne_Lals_SD, Mo_All_SD, Ly_Mals_SD, NRetic_Op_Mean, Eo_Lmals_Mean, Egc_All_Mean, Ly_Lals_SD, Ne_Lmals_SD, Ly_Op_SD, and combinations thereof.
In some aspects, the body fluid sample from a method such as described above may be whole blood. In some aspects, the one or more cell population parameters may comprise monocyte distribution width (MDW, also referred to as monocyte anisocytosis). MDW represents the volume distribution of the monocyte population. In some aspects, the one or more cell population parameters may be defined by a test order. In some aspects, the one or more cell population parameters may be compared to a threshold, such as a threshold value or a threshold range. In some aspects, a method such as described above may not subject the body fluid sample to dye prior to analysis. In some aspects, the MIS-C associated with SARS-CoV-2 may be suspected based on at least one cell population parameter, including, for example, MDW, being beyond a threshold value or a threshold range. In some aspects, in a method such as described above, the body fluid sample may be acquired from a hospitalized or non-hospitalized patient. In some aspects, in a method such as described above, the MIS-C associated with SARS-CoV-2 is evaluated automatically with a CBC differential test order.
As used herein, “patient” refers to a person or other animal from whom a body fluid sample is obtained, and may apply to research subjects, outpatients (people or animals seen for a brief visit with a medical practitioner, typically less than 1 day in duration, for medical assessment or treatment), inpatients (people or animals admitted to a medical care facility for 1 day or more, including, without limitation, hospitals, hospice care, rehabilitation facilities, and the like), or others. In some aspects, a patient may be under the current care of a clinician, such as a doctor, physician's assistant, nurse, nurse practitioner, chiropractor, surgeon, dentist, or the like. In some aspects, a “patient” may donate a sample without receiving medical assessment or treatment from the donation. In some aspects, the patient may be a pediatric patient. A pediatric patient may be up to 21 years of age. In some aspects, a pediatric patient may be at least 1 month of age and up to 21 years of age. In some aspects, a pediatric patient has an age of up to 21 years old, of up to 18 years old, and up to 16 years old. In some aspects, a pediatric patient has an age of up to one year old, up to two years old, and up to three years old.
Cellular analysis systems may use a variety of techniques to identify, count and/or characterize cells. For example, a cellular analysis system may use electrical impedance to determine the volume and quantity of cells passing through an interrogation zone in a flowcell. As another example, a cellular analysis system may use imaging technology to capture optical representations of the cell and analyze the optical representations (which might or might not be human-comprehensible or amenable to conversion to human-comprehensible images) to determine the size and quantity of cells in an interrogation zone, either in a quiescent system or in a flowcell. As yet another example, a cellular analysis system may use flow cytometry to irradiate cells passing through a flowcell and measure the transmission and/or scatter of the light as it passes through the cell. The light scatter may inherently distinguish different cells of different kinds, sizes or characteristics, or the cells may be prepared with markers, such as fluorescent markers, to facilitate the identification, quantification and/or characterization of the cells based on cellular features marked—or unmarked—by the marker.
A cellular analysis system may use combinations of these and/or other techniques to count, identify, and/or characterize cells. For example, a cellular analysis system may use a combination of electrical impedance and light scatter to analyze cells in a blood sample. If a combination of techniques is used, the techniques may employ hardware set up in serial progression (e.g., the same sample or aliquot of a sample is passed through multiple, separate interrogation zones), or in parallel progression (e.g., different aliquots of a sample are passed at essentially the same time through multiple, separate interrogation zones), or two or more techniques may be employed at the essentially the same time (e.g., a flow cell may be equipped to measure both electrical impedance and light scatter from the same sample or aliquot of sample in the same flow cell at essentially the same time). In this regard, essentially the same time means that the processes are running in overlapping time intervals for the same sample or different aliquots of the same sample. It is not essential to the practice of the invention that the different techniques be coordinated to occur at precisely the same time or in time intervals of equal duration.
A sample for analysis may be any biological fluid which contains cells. The biological fluid may, for example, be a body fluid sample such as blood. The sample may be whole blood, e.g., blood which has not been processed or modified except for the possible addition of an anticoagulant to prevent the blood from clotting, which would complicate flowing the blood through a flowcell for analysis. The sample may be processed, e.g., by dilution or by concentration. In some circumstances, the sample may be from a non-blood body fluid, such as urine, synovial fluid, saliva, bile, cerebrospinal fluid, amniotic fluid, semen, mucus, sputum, lymph, aqueous humour, tears, vaginal secretions, pleural fluid, pericardial fluid, peritoneal fluid, and the like. As with blood, if non-blood body fluids are sampled, the non-blood body fluids may be processed e.g., to achieve a desirable cellular concentration for analysis. A possible advantage of evaluating whole blood may be the relatively large number of cells available for analysis in a relatively small sample. A possible advantage of analyzing non-blood body fluids and/or processed blood may be pre-segregation of certain cells of interest and/or a reduction in the number of cells, because of differences in the types and number of cells that normally occur in different body fluids. A lower number of cells may be helpful, for example, for characterizing individual cells.
In some aspects, cells passing through a flowcell are analyzed using light scatter. As shown in
After aspiration, WBS 240 can be delivered to a preparation system 210. Preparation system 210 receives WBS 240 and can perform operations involved with preparing WBS 240 for further measurement and analysis. For example, preparation system 210 may separate WBS 240 into one or more predefined aliquots for presentation to transducer module 220. In some aspects, preparation system 210 may make no changes to the composition of WBS 240. Alternately, preparation system 210 may include mixing chambers so that appropriate reagents may be added to one or more of the aliquots. For example, where an aliquot is to be tested for differentiation of white blood cell subset populations, a lysing reagent (e.g., ERYTHROLYSE, a red blood cell lysing buffer) may be added to the aliquot to break up and remove the RBCs. Preparation system 210 may also include temperature control components to control the temperature of the reagents and/or mixing chambers. Appropriate temperature controls can improve the consistency of the operations of preparation system 210, and may facilitate pre-treatment of cells in the sample, e.g., with fluorescent markers, stains, or lyse.
In some instances, one or more predefined aliquots can be transferred from preparation system 210 to transducer module 220. As described in further detail below, transducer module 220 can perform light transmission, and/or light scatter measurements of cells from the WBS 240 passing individually therethrough. Measured light propagation (e.g., light transmission, light scatter) parameters can be provided or transmitted to analysis system 230 for data processing. In some instances, analysis system 230 may include computer processing features and/or one or more modules or components such as those described herein with reference to the system depicted in
As shown in
In some instances, the aliquot generally flows through the cell interrogation zone 332 such that its constituents pass through the cell interrogation zone 332 one at a time. In some cases, a system 300 may include a cell interrogation zone or other feature of a transducer module or blood analysis instrument such as those described in U.S. Pat. Nos. 5,125,737; 6,228,652; 7,390,662; 8,094,299; 8,189,187; and 9,939,453, the contents of which are incorporated herein by references for all purposes. For example, a cell interrogation zone 332 may be defined by a square transverse cross-section measuring approximately 50×50 microns, and having a length (measured in the direction of flow) of approximately 65 microns. Flow cell 330 may include an electrode assembly having first and second electrodes 334, 336 for performing DC impedance and/or RF conductivity measurements of the cells passing through cell interrogation zone 332.
Signals from electrodes 334, 336 can be transmitted to the analysis system 304. The electrode assembly can analyze volume and conductivity characteristics of the cells using low-frequency current and high-frequency current, respectively. For example, low-frequency DC impedance measurements can be used to analyze the volume of each individual cell passing through the cell interrogation zone. High-frequency RF current measurements can be used to determine the conductivity of cells passing through the cell interrogation zone. Because cell walls act as conductors to high frequency current, the high frequency current can be used to detect differences in the insulating properties of the cell components, as the current passes through the cell walls and through each cell interior. High frequency current can be used to characterize nuclear and granular constituents and the chemical composition of the cell interior.
The light source in
As shown in
A combination of UMALS and LMALS is defined as median angle light scatter (MALS), which may be light scatter or propagation at angles between about 9 degrees and about 43 degrees relative to the incoming beam axis which irradiates cells flowing through the interrogation zone. One of skill in the art will understand that these angles (and the other angles described herein) may vary somewhat based on the configuration of the interrogation, sensing and analysis systems.
As shown in
According to some embodiments, light scatter and transmission detector unit 350B may include a photoactive region or sensor zone for detecting and measuring light transmitted axially through the cells, or propagated from the irradiated cells, at an angle of about 0 degrees relative to the incoming light beam axis. In some cases, the photoactive region or sensor zone may detect and measure light propagated axially from cells at angles of less than about 1 degree relative to the incoming light beam axis. In some cases, the photoactive region or sensor zone may detect and measure light propagated axially from cells at angles of less than about 0.5 degrees relative to the incoming light beam axis less. Such axially transmitted or propagated light measurements correspond to axial light loss (ALL or a derivative thereof, e.g., AL2). As noted in previously incorporated U.S. Pat. No. 7,390,662, when light interacts with a particle, some of the incident light changes direction through the scattering process (i.e., light scatter) and part of the light is absorbed by the particles. Both of these processes remove energy from the incident beam. When viewed along the incident axis of the beam, the light loss can be referred to as forward extinction or axial light loss. Additional aspects of axial light loss measurement techniques are described in U.S. Pat. No. 7,390,662 at column 5, line 58 to column 6, line 4.
As such, the cellular analysis system 300 provides means for obtaining light propagation measurements, including light scatter and/or light transmission, for light emanating from the irradiated cells of the biological sample at any of a variety of angles or within any of a variety of angular ranges, including ALL and multiple distinct light scatter or propagation angles. For example, light detection assembly 350, including appropriate circuitry and/or processing units, provides a means for detecting and measuring UMALS, LMALS, LALS, MALS, and ALL.
Wires or other transmission or connectivity mechanisms can transmit signals from the electrode assembly (e.g. electrodes 334, 336), light scatter detector unit 350A, and/or light scatter and transmission detector unit 350B to the analysis system 304 for processing. For example, measured DC impedance, RF conductivity, light transmission, and/or light scatter parameters can be provided or transmitted to the analysis system 304 for data processing. In some instances, analysis system 304 may include computer processing features and/or one or more modules or components such as those described herein with reference to the system depicted in
As shown in
In some embodiments, module system 600 may include a storage subsystem 620 that can store the basic programming and data constructs that provide the functionality of the various techniques disclosed herein. For example, software modules implementing the functionality of method aspects, as described herein, may be stored in storage subsystem 620. These software modules may be executed by the one or more processors 604. In a distributed environment, the software modules may be stored on a plurality of computer systems and executed by processors of the plurality of computer systems. Storage subsystem 620 can include memory subsystem 622 and file storage subsystem 628. Memory subsystem 622 may include a number of memories including a main random access memory (RAM) 626 for storage of instructions and data during program execution and a read only memory (ROM) 624 in which fixed instructions are stored. File storage subsystem 628 can provide persistent (non-volatile) storage for program and data files, and may include tangible storage media which may optionally embody patient, treatment, assessment, or other data. File storage subsystem 628 may include a hard disk drive, a floppy disk drive along with associated removable media, a Compact Digital Read Only Memory (CD-ROM) drive, an optical drive, DVD, CD-R, CD RW, solid-state removable memory, other removable media cartridges or disks, and the like. One or more or all of the drives may be located at remote locations on other connected computers at other sites coupled to module system 600. In some instances, systems may include a computer-readable storage medium or other tangible storage medium that stores one or more sequences of instructions which, when executed by one or more processors, can cause the one or more processors to perform any aspect of the techniques or methods disclosed herein. One or more modules implementing the functionality of the techniques disclosed herein may be stored by file storage subsystem 628. In some embodiments, the software or code will provide protocol to allow the module system 600 to communicate with communication network 630. Optionally, such communications may include dial-up or internet connection communications.
System 600 can be configured to carry out various aspects of methods of the present disclosure. For example, processor component or module 604 can be a microprocessor control module configured to receive cellular parameter signals from a sensor input device or module 632, from a user interface input device or module 606, and/or from a diagnostic system 642, optionally via a diagnostic system interface 640 and/or a network interface 610 and a communication network 630. In some instances, sensor input device(s) may include or be part of a cellular analysis system that is equipped to obtain multiple light angle detection parameters, such as in a Beckman Coulter DxH™ hematology analyzer. In some instances, user interface input device(s) 606 and/or network interface 610 may be configured to receive cellular parameter signals generated by a cellular analysis system that is equipped to obtain multiple light angle detection parameters, such as a Beckman Coulter DxH™ Hematology Analyzer. In some instances, diagnostic system 642 may include or be part of a cellular analysis system that is equipped to obtain multiple light angle detection parameters, such as a Beckman Coulter DxH™ Hematology Analyzer.
Processor component or module 604 can also be configured to transmit cellular parameter signals, optionally processed according to any of the techniques disclosed herein or known to one of skill in the art, to sensor output device or module 636, to user interface output device or module 608, to network interface device or module 610, to diagnostic system interface 640, or any combination thereof. Each of the devices or modules according to embodiments of the present disclosure can include one or more software modules on a computer readable medium that is processed by a processor, or hardware modules, or any combination thereof. Any of a variety of commonly used platforms, such as Windows, MacIntosh, and Unix, along with any of a variety of commonly used programming languages, may be used to implement embodiments of the present disclosure.
User interface input devices 606 may include, for example, a touchpad, a keyboard, pointing devices such as a mouse, a trackball, a graphics tablet, a scanner, a joystick, a touchscreen incorporated into a display, audio input devices such as voice recognition systems, microphones, and other types of input devices. User input devices 606 may also download a computer executable code from a tangible storage media or from communication network 630, the code embodying any of the methods or aspects thereof disclosed herein. It will be appreciated that terminal software may be updated from time to time and downloaded to the terminal as appropriate. In general, use of the term “input device” is intended to include a variety of conventional and proprietary devices and ways to input information into module system 600.
User interface output devices 606 may include, for example, a display subsystem, a printer, a fax machine, or non-visual displays such as audio output devices. The display subsystem may be a cathode ray tube (CRT), a flat-panel device such as a liquid crystal display (LCD), a projection device, or the like. The display subsystem may also provide a non-visual display such as via audio output devices. In general, use of the term “output device” is intended to include a variety of conventional and proprietary devices and ways to output information from module system 600 to a user. In some instances, a cellular analysis system may not directly include a user interface output device, instead transferring data to a network, computer processor, or computer-readable non-transitory storage medium, with data display for a human user occurring in connection with that device or with devices to which the data from the cellular analysis system is further transferred after the initial transfer. If data is transferred from the analyzer without display, the data transferred may be raw sensor data or processed data or a combination of raw and processed data.
Bus subsystem 602 provides a mechanism for letting the various components and subsystems of module system 600 communicate with each other as intended or desired. The various subsystems and components of module system 600 need not be at the same physical location but may be distributed at various locations within a distributed network. Although bus subsystem 602 is shown schematically as a single bus, alternate embodiments of the bus subsystem may utilize multiple busses.
Network interface 610 can provide an interface to an outside network 630 or other devices. Outside communication network 630 can be configured to effect communications as needed or desired with other systems. It can thus receive an electronic packet from module system 600 and transmit any information as needed or desired back to module system 600. As depicted here, communication network 630 and/or diagnostic system interface 642 may transmit information to or receive information from a diagnostic system 642 that is equipped to obtain multiple light angle detection parameters, such as such as a Beckman Coulter DxH™ Cellular Analysis System. As non-limiting examples, outside communication network 630 may be used to transmit data between a cellular analysis system and a research database, a laboratory information system (LIS), an electronic medical record (EMR), and the like. In some instances, the communication may be one-way, with information flowing from the cellular analysis system to other systems. In some instances, the communication may be one-way with information (such as orders for specific measurements to be made or population parameters to be calculated) flowing from an external system, which may be remote or physically proximate to the cellular analysis system, to the cellular analysis system. In some instances, the communication may be two-way. In some instances, the information communicated to the cellular analysis system by an external system may include patient information useful in evaluating the significance of cellular measurements. For example, some reference ranges for hematology parameters may differ for pediatric populations or specific patient sub-populations relative to a general adult population, and the cellular analysis system may consider patient information when determining whether to flag analytical results for further review.
In addition to providing such infrastructure communications links internal to the system, the communications network system 630 may also provide a connection to other networks such as the internet and may comprise a wired, wireless, modem, and/or other type of interfacing connection.
It will be apparent to the skilled artisan that substantial variations may be used in accordance with specific requirements. For example, customized hardware might also be used and/or particular elements might be implemented in hardware, software (including portable software, such as applets), firmware, or combinations thereof. Further, connection to other computing devices such as network input/output devices may be employed. Module terminal system 600 itself can be of varying types including a computer terminal, a personal computer, a portable computer, a workstation, a network computer, or any other data processing system. Due to the ever-changing nature of computers and networks, the description of module system 600 depicted in
In some embodiments, the module system 600 can be configured to receive one or more cellular analysis parameters of a patient at an input module. Cellular analysis parameter data can be transmitted to an assessment module where raw sensor data or partially analyzed sensor data is further processed and/or evaluated in conjunction with additional information, possibly including prior laboratory results for the same patient; laboratory results from other types of analyzers or laboratory analyses; non-laboratory data about the patient, such as patient complaints, diagnostic history, vitals, or physical examination findings, or combinations thereof. The cellular analysis including a cell population parameter, such as WBC, MDW, NNRBC UMALS mean, and other cell population parameters can be output to a system user via an output module.
Analysis system 304 of transducer module 300 or other code programs 618 of module system 600 or both may comprise one or more algorithms for processing sensor data generated by transducer module 300. The one or more algorithms may process the sensor data to identify and count cells. For example, individual cells may be identifiable based on light scatter and/or light transmission data that provides an indication of the size and certain surface properties of the cells. As another example, electrical impedance may provide an indication of the size of the cell. Radiofrequency conductivity may provide an indication of cellular constituents that may be useful in distinguishing granulocytes and nucleated versus non-nucleated cells. Markers, stains, image analysis or other measurement techniques may be used to identify cells as, for example, NNRBC, WBC, monocytes, neutrophils, and the like. An algorithm may count the number of signals consistent with a given cell type during an interrogation period, which may be defined by time through a flowcell or imaging time, or may be defined by a volume of body fluid examined, or both.
In some instances, the signals produced are continuous or ordinal values, and the magnitude or other properties of the signals may be further analyzed. For example, higher electrical impedance values typically indicate a larger cell, and may be useful for identifying a particular cell. Electrical impedance values may also correlate to cell volume, and therefore the magnitude of the signals across many cells in the sample may also convey useful information about that sub-population of cells. For example, electrical impedance values may help identify monocytes and distribution features of the volumes for the monocytes as a sub-population of cells may convey information about MIS-C status.
Using a cellular analysis system such as described above, hematology markers may be identified and used in distinguishing hospitalized SARS-CoV-2 positive and MIS-C from outpatient SARS-CoV-2 positive and negative cases and hospitalized SARS-CoV-2 negative. Multiple studies assessing the effectiveness of such parameters have been performed, two of which are discussed below.
In a first study, particular markers and combinations of markers were identified in a study of data collected from 86 pediatric (1 to 18 years) patients, who presented to the emergency department. In the data, there were 16 hospitalized SARS-CoV-2 cases and 70 non-hospitalized SARS-CoV-2 cases. Of 16 hospitalized cases, 13 were MIS-C and 3 were Hospitalized-COVID positive; and of 70 non-hospitalized cases, 8 hospitalized COVID negative, 23 outpatient COVID positive, and 39 outpatient COVID negative. This data was used to statistically analyze the efficacy of 190 markers in determining MIS-C status. Specifically, for each marker, area under curve (AUC) was calculated using one predictor logistic regression model. Additionally, the cutoff and corresponding sensitivity, specificity, PPV and NPV were calculated using Youden's J statistic, a statistic that captures the performance of a dichotomous diagnostic test. The top 29 markers with an AUC of at least 80% which were identified in this analysis are presented below in Table 2.
In the table above (Table 2), and elsewhere in this document, the initial portion of the marker designation (e.g., in column 1 of Table 2), with the exception of the markers beginning with “Diff_” refers to the cell type or characteristic identified in column 2 of Table 2. Further, in the table above (Table 2), and elsewhere in this document, references to DC should be understood as referring to volume, references to OP or Op should be understood as referring to opacity, references to UMALS should be understood as referring to upper median angle light scatter, references to LMALS or Lmals should be understood as referring to lower median angle light scatter, references to MALS or Mals should be understood as referring to median angle light scatter (e.g., weighted sum of UMALS and LMALS), references to ALL or All should be understood as referring to axial light loss, references to AL2 should be understood as referring to a derivative of ALL which has been scaled and calibrated to compensate for manufacturing variation in optical components, references to LALS or lals should be understood as referring to low angle light scatter, references to DW should be understood as referring to distribution width (including, for example, monocyte distribution width (MDW) and lymphocyte distribution width (LDW)), references to SD should be understood as referring to standard deviation, and references to Mean should be understood as referring to the mean. For example, NRetic_Op_Mean should be understood as referring to the mean opacity for all mature red blood cells (i.e., those that are not retics). In another example, Mo_DC_SD should be understood as referring to the standard deviation in the volume of the monocytes. In Table 2 and elsewhere in this document, Diff_LDW_Value should be understood as the value reported for the lymphocyte distribution width (LDW). In some implementations, this may be used as a control as part of the MDW parameter, with lymphocyte distribution width (LDW, also referred to as Diff_LDW_Value). Rbc should be understood as red blood cell count, as further described in
In addition to analyzing individual markers using the calculations described above, an added value analysis was also conducted to determine the performance of MDW in conjunction with other markers. As shown in
In a second study, 699 children, ages 21 years and younger, presenting to a hospital with persistent fever were enrolled, and 822 blood samples were collected for analysis by a hematology analyzer. Of the 699 children, 424 children presented with symptoms concerning for infection, of whom 46 met the criteria for MIS-C and 94 of whom had acute COVID-19. Non-infectious (n=193) and healthy (n=90) controls were also enrolled. The average age of the participants was 10 years (range 4 days-21 years). Sex was equally distributed (52% male, 48% female). By race, participants were white (n=363, 52%), black (n=148), Asian (n=26), American Indian (n=3) and Hispanic (n−217). In this study, it was found that children with MIS-C displayed a significantly higher MDW (mean 31.7) than children with other infections, non-infectious illnesses, and healthy controls (mean MDW 23.8, 19.5, and 16.7, respectively). Differences between multiple groups were analyzed using the one-way-ANOVA parametric test with Tukey's posthoc test. Differences were considered statistically significant for p<0.05. Dependencies between blood parameters were calculated using Pearson's correlation coefficients, with correlations assumed to be significant for p<0.05. A Receiver Operator Curve (ROC) was calculated for the ability of MDW in distinguishing MIS-C from children presenting with other infections.
In this study, receiver-operating classification (ROC) analysis revealed that a MDW biomarker would have an 82% diagnostic accuracy identifying children with MIS-C in a population of children presenting with symptoms of infection. As such, when a child presents with non-specific symptoms of infection in the setting of high community rates of COVID-19, this study indicated that, as shown in
The second study further sought to assess whether age would impact MDW values across the cohort, regardless of diagnosis or symptoms. Consistent with previous studies reporting MDW values are slightly higher in younger children compared to older children and young adults, MDW was found to be increased in younger children), with children <2 years of age having the highest MDW (mean 25.3) and children >16 years of age having the lowest MDW (mean 20.1). This can be seen in
This second study also sought to assess whether MDW would distinguish MIS-C from acute pediatric SARS-CoV-2 infection. The study found that MDW was significantly elevated in children with MIS-C as compared to children with acute COVID-19. This result can be seen in
This study further indicated that, not only was MDW useful in identifying MIS-C, it could also aid in tracking disease resolution. In the study, MDW was measured at multiple time points in children with MIS-C and individual values were plotted over time: prior to administration of MIS-C therapies (immunoglobulin or steroids) or within 24 hours of admission, during hospital course, and at follow-up. This can be seen in
Beyond MDW, this second study also indicated that additional cell population parameters, as shown in Table 3 could also be useful in diagnosing and/or tracking the progress of MIS-C.
As noted previously in the context of the first study, combinations of markers may also be used to provide further power for detecting MIS-C. For example, the combinations of markers set forth in table 4 were found to have an AUC of at least 0.99, and the combinations of markers set forth in table 5 were found to have an AUC of at least
In general, it is believed that combinations of parameters (e.g., parameters from Tables 2 and/or 3) related to different types of cells may provide information which could be more effective in detecting MIS-C than information from any of the individual parameters. Thus, a combination which includes one parameter from two or more of the following groups: monocyte parameters (e.g., MDW), granulocyte parameters (e.g., Ne_DC_SD, Egc_Lmals_Mean), red blood cell parameters (e.g., Hgb), lymphocyte parameters (e.g., Ly_All_SD), and eosinophil parameters (e.g., Eo_All_Mean), is expected to be useful in detecting MIS-C. Additionally, it is believed that combinations of parameters related to monocytes, granulocytes (e.g., neutrophils), and red blood cells are likely to be useful in detecting MIS-C, as monocytes, granulocytes, and red blood cells share a common progenitor cell in bone marrow. Additionally, lymphocyte parameters would also be expected to be relevant in such combinations, and so a four parameter combination such as MDW+Ne_DC_Mean+Rbc+Ly_All_SD would be expected to be suitable for use in detecting MIS-C, though other combinations (e.g., combinations with fewer parameters, such as shown in Tables 4 and 5) are also possible, and so the above description should be understood as being illustrative only, and should not be treated as limiting.
As further described above, various parameters and combinations of parameters may be used in addressing (including, for example, identifying or treating) MIS-C. For example, a system may be implemented to, based on measurements of a cell population parameter (including, for example, those shown in Table 2 or Table 3) either individually or in combination, rapidly detect and report SARS-CoV-2 associated MIS-C. In another example, a method may include detecting MIS-C or detecting the severity of MIS-C in a patient, based at least in part on a measurement of a cell population parameter, either alone or in combination. The MIS-C may preferably be SARS-CoV-2 associated MIS-C. In some aspects, the cell population parameter preferable includes MDW, either alone or in combination with one more additional cell population parameters. In some aspects, the method of detecting MIS-C or detecting the severity of MIS-C in a patient may further include assessing an additional parameter recommended for assessing MIS-C such as complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), interleukin 6 (IL-6), and albumin.
In some aspects, if one of the cell population parameters described herein or a combination of those cell population parameters is greater than a threshold value, this could be treated as indicating MIS-C. A threshold value may be determined by a person having skill in the art for the specific patient population being examined. In some aspects, the threshold value may include a Youden cutoffs set forth in Table 2. In some aspects, including, for example when the patient is a pediatric patient, the threshold value for MDW may be at least 23, or at least 24. In some aspects, the threshold value for MDW may be at least 24, a value indicating MIS-C, as described in the second study. In some aspects, including, for example when the patient is a pediatric patient, the threshold value for MDW may be up to 31. In some aspects, the threshold value for MDW may be age-adjusted. For example, when the patient is a pediatric patient of up to 1 year of age, up to 2 years of age, or up to 3 years of age, the threshold value or threshold range for MDW may be age-adjusted.
In some aspects, cell population parameters including those shown in Table 2 or Table 3 may be used in determining timing and/or administration of treatment for MIS-C cases. For example, MDW values may be used as an aid in determining risk for certain complications associated with MIS-C and/or for selecting patients for whom particular therapies are appropriate. An appropriate therapy may be selected by the patient's physician depending on the MDW value; exemplary therapies might include extracorporeal membrane oxygenation (ECMO), intravenous immunoglobulin (IVIG), steroids, and vasopressors. In another example, MDW values, and in particular declining MDW values, may be used in evaluating efficacy of treatment. When, for example, treatment is determined to be efficacious based on declining MDW values, a clinician may be able to more accurately determine when a hospitalized MIS-C cases may be appropriately de-escalated and/or discharged. A threshold value for determining when a patient may be de-escalated and/or discharged may be determined by a person having skill in the art for the specific patient population being examined. For example, a threshold value for determining when a patient may be de-escalated and/or discharged may be determined by the mean value of the cell population parameter in a normal population. In some aspects, including, for example when the patient is a pediatric patient, the threshold value of MDW for de-escalation and/or discharge may be up to 20, up to 21, up to 22, up to 23, or up to 24. For example, in some aspects, the threshold value of MDW for de-escalation and/or discharge may be up to 20, as shown in
One of skill in the art will understand that the methods, systems and parameters described are not intended to exhaustively describe all possible implementations of the disclosed technology. For example, while the disclosed techniques may be implemented using systems which perform analysis on samples of blood in a near-native state, the described approach of determining MIS-C using hematology parameters may also be useful for analyzers which use fluorescent staining or similar treatment on their samples. Similarly, the described approach of determining MIS-C using hematology parameters may also be useful when performed using other parameters, such as parameters which, like MDW, may reflect variation in immune cell population. Exemplary other parameters include the NEMO score, described in Urrechaga, et. al., Role of Leucocytes Cell Population Data in Early Detection of Sepsis, J. C
The following examples relate to various non-exhaustive ways in which the teachings herein may be combined or applied. It should be understood that the following examples are not intended to restrict the coverage of any claims that may be presented at any time in this application or in subsequent filings of this application. No disclaimer is intended. The following examples are being provided for nothing more than merely illustrative purposes. It is contemplated that the various teachings herein may be arranged and applied in numerous other ways. It is also contemplated that some variations may omit certain features referred to in the below examples. Therefore, none of the aspects or features referred to below should be deemed critical unless otherwise explicitly indicated as such at a later date by the inventors or by a successor in interest to the inventors. If any claims are presented in this application or in subsequent filings related to this application that include additional features beyond those referred to below, those additional features shall not be presumed to have been added for any reason relating to patentability.
An automated system for evaluating MIS-C associated with SARS-CoV-2, the system comprising: a light source configured to irradiate cells of a body fluid sample; one or more light scatter detector units configured to measure light scattered from the light source scattered by the cells in the body fluid sample; a data processing module comprising a processor and a non-transitory computer readable medium, wherein the non-transitory computer readable medium stores instructions that, when executed by the processor, configure the processor to perform a method comprising: analyzing a monocyte or granulocyte cell population parameter determined for the body fluid sample based on data from the electrode assembly and the one or more light scatter detector units; and evaluating MIS-C associated with SARS-CoV-2 based at least in part on the monocyte or granulocyte population parameter.
The system of example 1, wherein analyzing the monocyte or granulocyte cell population parameter comprises analyzing a monocyte cell population parameter.
The system of example 2, wherein the monocyte cell population parameter comprises MDW.
The system of example 1, wherein analyzing the monocyte or granulocyte cell population parameter comprises analyzing a granulocyte cell population parameter.
The system of example 4, wherein the granulocyte cell population parameter comprises EGC.
The system of example 4, wherein the granulocyte cell population parameter comprises IG COUNT.
The system of example 1, wherein analyzing the monocyte or granulocyte cell population parameter comprises analyzing standard deviation of neutrophil volume.
The system of example 1, wherein analyzing the monocyte or granulocyte cell population parameter comprise analyzing standard deviation of neutrophil volume and EGC_LMALS_MEAN.
The system of example 1, wherein analyzing the monocyte or granulocyte cell population parameter comprises comparing one or more cell population parameters comprising the monocyte or granulocyte cell population parameter to a threshold.
The system of any of examples 1-9, wherein the system comprises an electrode assembly configured to measure direct current (DC) impedance of cells of the body fluid sample.
The system of any of examples 1-10, wherein evaluating MIS-C associated with SARS-CoV-2 based at least in part on the monocyte or granulocyte population parameter comprises evaluating the monocyte or granulocyte population parameter in combination with an additional parameter recommended for assessing MIS-C.
The system of example 11, wherein the additional parameter recommended for assessing MIS-C is selected from a group consisting of: complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), interleukin 6 (IL-6), or albumin, and a combination thereof.
The system of any of examples 1-10, wherein evaluating MIS-C associated with SARS-CoV-2 based at least in part on the monocyte or granulocyte population parameter comprises analyzing evaluating a combination of parameters comprising at least two parameters selected from the group consisting of: a monocyte cell population parameter, a granulocyte cell population parameter, and a red blood cell population parameter.
The system of example 13, wherein: the monocyte cell population parameter is a parameter selected from a group consisting of: MDW, Mo_DC_SD, Mo_DC_Mean, Mo_All_SD, RE-MONO; the granulocyte cell population parameter is a parameter selected from a group consisting of: Ne_DC_Mean, Egc_Lmals_Mean, Egc_Mals_Mean, Ne_Lmals_Mean, Ne_Mals_Mean, Ne_All_SD, Ne_DC_SD, Ne_All_Mean, Ne_Lals_SD, Egc_All_Mean, Ne_Lmals_SD, Egc_Op_Mean, Egc_Umals_SD, NEUT-GI, NEUT-RI, and IG COUNT; the red blood cell population parameter is a parameter selected from a group consisting of: Rbc, Hgb, Hct, NNrbc_Op_SD, Nretic_Op_Mean, NrbcAL2Mean, HYPO-HE, HYPER-HE, RET-HE, NRBC, MICROR, MACROR, and FRC.
The system of any of examples 13-14, wherein the combination of parameters comprises a lymphocyte cell population parameter.
The system of example 15, wherein the lymphocyte cell population parameter is selected from a group consisting of: Ly_DC_SD, Ly_All_SD, Ly_All_SD, Ly_Lmals_SD, Ly_Mals_SD, Ly_Lals_SD, Ly_Op_SD, RE-LYMP, and AS-LYMP.
A method for evaluating MIS-C associated with SARS-CoV-2, the method comprising: flowing a body fluid sample through a flowcell; determining one or more cell population parameters for the body fluid sample, wherein the one or more cell population parameters comprises a parameter for variability of immune cells in the body fluid sample; evaluating MIS-C associated with SARS-CoV-2 based at least in part on the one or more cell population parameters.
The method of example 17, wherein the parameter for variability of immune cells in the body fluid sample comprises NEMO score.
The method of example 17 or 18, wherein the parameter for variability of immune cells in the body fluid sample comprises MDW.
The method of example 19, wherein evaluating MIS-C associated with SARS-CoV-2 based at least in part on the one or more cell population parameters comprises determining that a patient from whom the body fluid sample was obtained has or is at risk of developing MIS-C when MDW is above a threshold.
The method of example 20, wherein the threshold for MDW is selected from a group consisting of at least 23 and at least 24.
The method of example 19, wherein evaluating MIS-C associated with SARS-CoV-2 based at least in part on the one or more cell population parameters comprises determining that a patient from whom the body fluid sample was obtained is eligible for discharge or de-escalation when the monocyte or granulocyte population parameter is below a threshold.
The method of example 22, wherein the threshold for MDW is selected from a group consisting of up to 20, up to 21, up to 22, up to 23 and up to 24.
The method of any of examples 20-23, wherein the threshold is age adjusted.
The method of example 17, wherein the one or more cell population parameters comprise a combination selected from the group consisting of: MDW and EGC; MDW and NE_DC_SD; and MDW, NE_DC_SD, and EGC_LMALS_MEAN.
The method of any of examples 17-25, wherein the body fluid sample is acquired from a pediatric patient.
The method of example 26, wherein the pediatric patient has an age from a group consisting of: up to 21 years old, up to 18 years old, and up to 16 years old.
The method of example 26, wherein the pediatric patient has an age from a group consisting of: up to one year old, up to two years old, and up to three years old.
The method of any of example 26, 26A or 26B, wherein the pediatric patient is at least one month old.
A method for evaluating MIS-C associated with SARS-CoV-2, the method comprising: flowing a body fluid sample through a flowcell; irradiating a plurality of cells in the body fluid sample in the flowcell; measuring light scatter from individual cells of the plurality of cells; analyzing a monocyte or granulocyte cell population parameter determined for the body fluid sample based on the light scatter; and evaluating MIS-C associated with SARS-CoV-2 based at least in part on the monocyte or granulocyte population parameter.
The method of example 27 wherein the body fluid sample is whole blood.
The method of example 27 or example 28 wherein analyzing the monocyte or granulocyte cell population parameter comprises analyzing a monocyte cell population parameter.
The method of example 29, wherein the monocyte cell population parameter comprises MDW.
The method of example 27 or example 28 wherein analyzing the monocyte or granulocyte cell population parameter comprises analyzing a granulocyte cell population parameter.
The method of example 31, wherein the granulocyte cell population parameter comprises EGC.
The method of example 31, wherein the granulocyte cell population parameter comprises IG COUNT.
The method of any of examples 27-33 wherein the monocyte or granulocyte cell population parameter is defined by a test order.
The method of any of examples 27-34 wherein analyzing the monocyte or granulocyte cell population parameter comprises comparing one or more cell population parameters comprising the monocyte or granulocyte cell population parameter to a threshold range.
The method of any of examples 27-35 wherein the method does not subject the sample to dye prior to analysis.
The method of any of examples 27-36 wherein the MIS-C associated with SARS-CoV-2 is suspected based on at least one cell population parameter being beyond a threshold range.
The method of example 37 wherein the at least one cell population parameter being beyond its threshold range is MDW.
The method of any of examples 27-38, wherein evaluating MIS-C associated with SARS-CoV-2 based at least in part on the monocyte or granulocyte population parameter comprises determining that a patient from whom the body fluid sample was obtained has or is at risk of developing MIS-C when the monocyte or granulocyte population parameter is above a threshold.
The method of example 39, wherein the monocyte or granulocyte population parameter comprises MDW, and wherein the threshold for MDW is selected from a group consisting of at least 23 and at least 24.
The method of any of examples 27-38, wherein evaluating MIS-C associated with SARS-CoV-2 based at least in part on the monocyte or granulocyte population parameter comprises determining that a patient from whom the body fluid sample was obtained is eligible for discharge or de-escalation when the monocyte or granulocyte population parameter is below a threshold.
The method of example 41, wherein the monocyte or granulocyte population parameter comprises MDW, and wherein the threshold for MDW is selected from a group consisting of up to 20, up to 21, up to 22, up to 23 and up to 24.
The method of any of examples 38-42, wherein the threshold is age adjusted.
The method of any of examples 27-43 wherein the body fluid sample is acquired from a hospitalized or non-hospitalized patient.
The method of any of examples 27-44 wherein MIS-C associated with SARS-Cov-2 is evaluated automatically with a CBC with differential test order.
The method of any of examples 27-45, wherein the body fluid sample is acquired from a pediatric patient.
The method of example 46, wherein the pediatric patient has an age from a group consisting of: up to 21 years old, up to 18 years old, and up to 16 years old.
The method of example 46, wherein the pediatric patient has an age from a group consisting of: up to one year old, up to two years old, and up to three years old.
The method of example 46, 46A, or 46B, wherein the pediatric patient is at least one month old.
The method of any of examples 27-46, wherein evaluating MIS-C associated with SARS-CoV-2 based at least in part on the monocyte or granulocyte population parameter comprises evaluating the monocyte or granulocyte population parameter in combination with an additional parameter recommended for assessing MIS-C.
The method of example 47, wherein the additional parameter recommended for assessing MIS-C is selected from a group consisting of: complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin lactic acid dehydrogenase (LDH), interleukin 6 (IL-6), or albumin, and a combination thereof.
The method of any of examples 27-46, wherein evaluating MIS-C associated with SARS-CoV-2 based at least in part on the monocyte or granulocyte population parameter comprises analyzing evaluating a combination of parameters comprising at least two parameters selected from the group consisting of: a monocyte cell population parameter, a granulocyte cell population parameter, and a red blood cell population parameter.
The method of example 49, wherein: the monocyte cell population parameter is a parameter selected from a group consisting of: MDW, Mo_DC_SD, Mo_DC_Mean, Mo_All_SD, RE-MONO; the granulocyte cell population parameter is a parameter selected from a group consisting of: Ne_DC_Mean, Egc_Lmals_Mean, Egc_Mals_Mean, Ne_Lmals_Mean, Ne_Mals_Mean, Ne_All_SD, Ne_DC_SD, Ne_All_Mean, Ne_Lals_SD, Egc_All_Mean, Ne_Lmals_SD, Egc_Op_Mean, Egc_Umals_SD, NEUT-GI, NEUT-RI, and IG COUNT; the red blood cell population parameter is a parameter selected from a group consisting of: Rbc, Hgb, Hct, NNrbc_Op_SD, Nretic_Op_Mean, NrbcAL2Mean, HYPO-HE, HYPER-HE, RET-HE, NRBC, MICROR, MACROR, and FRC.
The method of any of examples 49-50, wherein the combination of parameters comprises a lymphocyte cell population parameter.
The method of example 51, wherein the lymphocyte cell population parameter is selected from a group consisting of: Ly_DC_SD, Ly_All_SD, Ly_All_SD, Ly_Lmals_SD, Ly_Mals_SD, Ly_Lals_SD, Ly_Op_SD, RE-LYMP, and AS-LYMP.
A method for detecting or detecting the severity of MIS-C in a patient, the method comprising: providing a sample from the patient; determining the value of a cell population parameter in the patient, wherein the cell population parameter comprises a monocyte or granulocyte population parameter; and determining whether said patient has an increased risk of suffering MIS-C based on the value of the cell population parameter.
The method of example 53, wherein the patient is known to have been exposed to SARS-CoV-2 or suspected to have been exposed to SARS-CoV-2.
The method of example 53 or 54, wherein the patient is a pediatric patient.
The method of example 55, wherein the pediatric patient has an age from a group consisting of: up to 21 years old, up to 18 years old, and up to 16 years old.
The method of example 55, wherein the pediatric patient has an age from a group consisting of: up to one year old, up to two years old, and up to three years old.
The method of any of examples 55, 55A or 55B, wherein the pediatric patient is at least one month old.
The method of any of examples 53 to 55, wherein the cell population parameter comprises MDW.
The method of example 56, wherein the method further comprises comparing the cell population parameter to a threshold value or a threshold range.
The method of example 57, wherein determining whether said patient has an increased risk of suffering MIS-C based on the value of the cell population parameter comprises determining that the patient has or is at risk of developing MIS-C when the cell population parameter is greater than the threshold value.
The method of example 58, wherein the cell population parameter comprises MDW, and wherein the threshold value for MDW is at least 23, or at least 24.
The method of example 57, wherein determining whether said patient has an increased risk of suffering MIS-C based on the value of the cell population parameter comprises determining the patient is eligible for de-escalation and/or discharge when the cell population parameter is less than the threshold value.
The method of example 60, wherein the monocyte cell population parameter comprises MDW, and wherein the threshold value for MDW is up to 20, up to 21, up to 22, up to 23, or up to 24.
The method of any of examples 57 to 61, wherein the threshold value or the threshold range is age-adjusted.
The method of any of examples 57 to 61, wherein the method further comprises measuring an additional parameter recommended for assessing MIS-C.
The method of example 63, wherein the additional parameter recommended for assessing MIS-comprises complete blood count (CBC), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), fibrinogen, procalcitonin, d-dimer, ferritin, lactic acid dehydrogenase (LDH), interleukin 6 (IL-6), or albumin, or a combination thereof.
The method of any of examples 53-62, wherein determining whether said patient has the increased risk of suffering MIS-C based on the value of the cell population parameter comprises evaluating a combination of parameters comprising at least two parameters selected from the group consisting of: a monocyte cell population parameter, a granulocyte cell population parameter, and a red blood cell population parameter.
The method of example 65, wherein: the monocyte cell population parameter is a parameter selected from a group consisting of: MDW, Mo_DC_SD, Mo_DC_Mean, Mo_All_SD, RE-MONO; the granulocyte cell population parameter is a parameter selected from a group consisting of: Ne_DC_Mean, Egc_Lmals_Mean, Egc_Mals_Mean, Ne_Lmals_Mean, Ne_Mals_Mean, Ne_All_SD, Ne_DC_SD, Ne_All_Mean, Ne_Lals_SD, Egc_All_Mean, Ne_Lmals_SD, Egc_Op_Mean, Egc_Umals_SD, NEUT-GI, NEUT-RI, and IG COUNT; the red blood cell population parameter is a parameter selected from a group consisting of: Rbc, Hgb, Hct, NNrbc_Op_SD, Nretic_Op_Mean, NrbcAL2Mean, HYPO-HE, HYPER-HE, RET-HE, NRBC, MICROR, MACROR, and FRC.
The method of any of examples 65-66, wherein the combination of parameters comprises a lymphocyte cell population parameter.
The method of example 67, wherein the lymphocyte cell population parameter is selected from a group consisting of: Ly_DC_SD, Ly_All_SD, Ly_All_SD, Ly_Lmals_SD, Ly_Mals_SD, Ly_Lals_SD, Ly_Op_SD, RE-LYMP, and AS-LYMP.
The dimensions and values disclosed herein are not to be understood as being strictly limited to the exact numerical values recited. Instead, unless otherwise specified, each such dimension is intended to mean both the recited value and a functionally equivalent range surrounding that value to include at least the variability due to the reproducibility of measurements made using the test methods described herein, or industry-standard test methods if no test method is expressly disclosed.
Every document cited herein, including any cross referenced or related patent or application, is hereby incorporated herein by reference in its entirety unless expressly excluded or otherwise limited. The citation of any document is not an admission that it is prior art with respect to any invention disclosed or claimed herein or that it alone, or in any combination with any other reference or references, teaches, suggests or discloses any such invention. Further, to the extent that any meaning or definition of a term in this document conflicts with any meaning or definition of the same term in a document incorporated by reference, the meaning or definition assigned to that term in this document shall govern.
While particular embodiments of the present invention have been illustrated and described, it would be obvious to those skilled in the art that various other changes and modifications can be made without departing from the spirit and scope of the invention. It is therefore intended to cover in the appended claims all such changes and modifications that are within the scope of this invention.
In this document, including the examples and claims, a statement that something is “based on” something else should be understood to mean that it is determined at least in part by the thing that it is indicated as being based on. To indicate that something must be completely determined based on something else, it is described as being “based EXCLUSIVELY on” whatever it must be completely determined by.
This is related to, and claims the benefit of, provisional patent application 63/083,519, titled “Methods for Evaluating MIS-C Associated with COVID-19 in Pediatric Patients”, filed in the United States Patent Office on Sep. 25, 2020. That application is hereby incorporated by reference in its entirety.
This invention was made with government support under contract number 75A50120C00189 awarded by the biomedical advanced research and development authority (BARDA) of the office of the assistant secretary for preparedness and response in the department of health and human services, under contract number GM092804 awarded by the National Institutes of Health, under contract number HD089939 awarded by the National Institutes of Health, and under contract number HL143183 awarded by the National Institutes of Health. The government has certain rights in the invention.
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/US21/51999 | 9/24/2021 | WO |
| Number | Date | Country | |
|---|---|---|---|
| 63083519 | Sep 2020 | US |
